APA (7th ed.) Citation
(2026). Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. Biologics: Targets & Therapy.
Chicago Style (17th ed.) Citation
"Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development." Biologics: Targets & Therapy 2026.
MLA (9th ed.) Citation
"Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development." Biologics: Targets & Therapy, 2026.
Warning: These citations may not always be 100% accurate.